Clinigen Group plc Clinigen launches Japanese business
October 18 2016 - 2:01AM
RNS Non-Regulatory
TIDMCLIN
Clinigen Group plc
18 October 2016
18 October 2016
Clinigen launches Japanese business to strengthen Asian
presence
Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the
global pharmaceuticals and services group, has launched its
Japanese business with the opening of an office in Tokyo, Japan.
The establishment of Clinigen KK further expands the Group's
presence in Asia, following Clinigen's acquisition of Link
Healthcare in 2015.
Alongside the launch, Clinigen KK will transfer the Marketing
Authorisation for its lead Specialty Pharmaceutical (SP) product
Foscavir(R) (foscarnet sodium) back from Nobel Pharma on 1 November
2016. Nobel Pharma has been the distribution partner for Foscavir
in Japan since 2011.
Foscavir is indicated to treat cytomegalovirus (CMV) retinitis
in patients with acquired immunodeficiency syndrome (AIDS) or
Cytomegalovirus viremia and cytomegalovirus disease in
hematopoietic stem cell transplant (HSCT) patients. Japan was the
first market where Clinigen successfully achieved a new license
extension for HSCT patients in 2011.
Japan remains an important market for Foscavir with more than
2,000 patients treated annually. Clinigen will assume full
marketing and distribution responsibility for Foscavir from
November, to supply the product to healthcare professionals and
patients across Japan.
Clinigen KK is a significant milestone for the Group in
expanding its global footprint as Japan is the second largest
pharmaceutical market globally. The Japanese business will allow
the Group to supply and distribute both licensed and unlicensed
medicines in the country, providing additional infrastructure to
support Clinigen's mission to deliver the right medicine to the
right patient at the right time.
Clinigen employs over 500 people globally, across 11 locations.
The opening of the Japanese office further expands its
international supply chain and operational network.
Shaun Chilton, Chief Executive Officer-designate, said:
"We are focused on building our market leadership positions by
expanding in key geographic regions to drive sustained organic
growth and better address unmet patient needs for access to
critical medicines.
"The opening of our Japanese business helps support our goals
and will enable us to effectively serve the Japanese market by
supplying our own products, beginning with Foscavir.
"At a time when many pharmaceutical and biotechnology companies
are looking for specialist partners to work with them in Asia, the
opening of our Japanese office gives us more opportunities to
provide customers with our global expertise combined with local
knowledge."
- Ends -
Contact details
Clinigen Group plc Tel: +44 (0) 1283
495010
Shaun Chilton, Chief Executive
Officer-designate
Martin Abell, Chief Financial
Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
Peel Hunt LLP - Joint Broker Tel: +44 (0) 20
7418 8900
James Steel / Dr Christopher
Golden
Instinctif Partners Tel: +44 (0) 20
7457 2020
Melanie Toyne-Sewell / Jen
Lewis / Jayne Crook Email: clinigen@instinctif.com
About Foscavir(R) (foscarnet sodium)
Foscavir(R) is licensed for the treatment of cytomegalovirus
(CMV) retinitis in HIV patients, and acyclovir-resistant
mucocutaneous herpes simplex virus (HSV) infections in
immunocompromised patients.
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time and is focused in
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in
the management and supply of commercial medicines for clinical
trials.
The Group is also the trusted global leader in ethically
sourcing and supplying unlicensed medicines to hospital pharmacists
and physicians for patients with a high unmet need, through three
of its divisions: Idis Managed Access runs early access programs
for innovative new medicines. Idis Global Access and Link
Healthcare work directly with healthcare professionals to enable
compliant access to unlicensed medicines on a global basis and
niche essential licensed and generic medicines across Australasia,
Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights,
revitalises and markets its own portfolio of niche hospital
medicines.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFFDFMWFMSEDS
(END) Dow Jones Newswires
October 18, 2016 02:01 ET (06:01 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024